| Wissenschaftl. Titel | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk |
| Erkrankung |
Niere/Harnwege:
Nierenzellkrebs:
neoadjuvant
|
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
erstellt 20.04.2020 Student Studienregister
geändert 20.01.2023 Nicole Wamser